rea cream to prevent Capecitabine related Hand Foot Syndrome: a Randomized Controlled trial
Phase 3
Completed
- Conditions
- Health Condition 1: C50-C50- Malignant neoplasms of breastHealth Condition 2: C15-C26- Malignant neoplasms of digestive organs
- Registration Number
- CTRI/2022/10/046534
- Lead Sponsor
- no sponsor
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 228
Inclusion Criteria
Patients with gastrointestinal malignancies of breast cancer initiating capecitabine treatment at a dose of at least 1000mg/m2 twice daily as monotherapy or combination therapy, ECOG PS less than 3, adequate bone marrow function
Exclusion Criteria
Patients with any dermatological toxicity other than alopecia that has not resolved, creatinine clearance of <30ml/min as per Cockcroft gault formula
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method